Vivanza Biosciences Ltd Upgraded to Sell on Technical and Valuation Improvements

Technical Trends Show Signs of Stabilisation

The most significant driver behind the upgrade is the change in the technical grade from bearish to mildly bearish. While the weekly Moving Average Convergence Divergence (MACD) remains bearish, the monthly MACD has turned mildly bullish, signalling a potential shift in momentum over the longer term. Similarly, the Know Sure Thing (KST) indicator reflects a bearish stance on the weekly chart but a mildly bullish trend monthly, indicating some underlying strength building up.

Other technical indicators present a mixed picture. The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, suggesting the stock is neither overbought nor oversold. Bollinger Bands remain mildly bearish on both timeframes, while daily moving averages continue to be bearish. The Dow Theory does not indicate any definitive trend on weekly or monthly scales, and On-Balance Volume (OBV) data is inconclusive.

Despite these mixed signals, the stock price has shown resilience, closing at ₹1.91 on 7 April 2026, up 4.95% from the previous close of ₹1.82. The intraday range was narrow, between ₹1.86 and ₹1.91, with the 52-week high at ₹2.94 and low at ₹1.86. This technical improvement has contributed materially to the upgrade in the investment rating.

Valuation Moves from Attractive to Fair

Vivanza Biosciences’ valuation grade has been downgraded from attractive to fair, reflecting a recalibration of its price multiples and profitability metrics. The company’s price-to-earnings (PE) ratio stands at a negative -50.93, indicative of losses or negative earnings, while the price-to-book value is 1.66, suggesting the stock trades modestly above its book value. Enterprise value to EBIT and EBITDA ratios are both negative at -17.18, further signalling operational losses.

Return on Capital Employed (ROCE) is slightly negative at -0.64%, and Return on Equity (ROE) is also negative at -6.72%, underscoring weak profitability. Compared to peers in the Pharmaceuticals & Biotechnology sector, Vivanza’s valuation is more conservative, trading at a discount relative to companies like Arfin India and Jindal Photo, which are classified as very expensive with PE ratios exceeding 90.

Despite the downgrade in valuation grade, the fair rating reflects a more realistic assessment of the company’s current financial health and market pricing, balancing the risks of ongoing losses with the potential for recovery.

Financial Trend Remains Challenging

Financially, Vivanza Biosciences continues to face headwinds. The company’s operating profits have declined at a compound annual growth rate (CAGR) of -4.85% over the past five years, signalling deteriorating core earnings. The debt servicing capacity is weak, with a Debt to EBITDA ratio of -10.14 times, indicating high leverage relative to earnings before interest, taxes, depreciation, and amortisation.

Return on Equity averaged 9.70%, which is low for the sector and suggests limited profitability per unit of shareholder funds. The company’s net sales for the latest six months rose to ₹100.61 crores, and profit after tax (PAT) was ₹0.76 crores, showing some positive momentum in recent quarters. However, over the past year, the stock has generated a negative return of -16.23%, underperforming the Sensex, which gained 2.02% over the same period.

Longer-term returns are even more concerning, with a five-year return of -85.08% compared to the Sensex’s 50.25% gain, and a ten-year return of -73.89% against a Sensex rise of 202.27%. This underperformance highlights structural challenges in the company’s business model and market positioning.

Quality Parameters Show Limited Improvement

Quality metrics remain subdued, reflecting the company’s micro-cap status and operational difficulties. The company’s Mojo Score is 31.0, with a Mojo Grade upgraded from Strong Sell to Sell, indicating a slight improvement but still a cautious stance. Majority shareholders are non-institutional, which may limit access to strategic capital and long-term stability.

While recent quarterly results for Q3 FY25-26 showed positive financial performance, the overall quality of earnings and balance sheet strength remain below par. The company’s ability to generate consistent returns and service debt remains a concern for investors seeking stability in the Pharmaceuticals & Biotechnology sector.

Stock Performance Relative to Benchmarks

Vivanza Biosciences’ stock performance has been volatile and generally disappointing relative to benchmark indices. Over the past week, the stock returned 8.52%, outperforming the Sensex’s 3.71% gain, suggesting some short-term buying interest. However, over one month, the stock declined by 3.05%, slightly better than the Sensex’s 5.45% fall.

Year-to-date returns stand at -13.18%, marginally worse than the Sensex’s -12.44%. The one-year return of -16.23% contrasts sharply with the Sensex’s positive 2.02%, while the three-year and five-year returns are not available or deeply negative, underscoring persistent underperformance. This trend highlights the stock’s risk profile and the need for cautious investor consideration.

Conclusion: A Cautious Upgrade Reflecting Mixed Signals

The upgrade of Vivanza Biosciences Ltd’s investment rating from Strong Sell to Sell reflects a cautious optimism driven primarily by technical improvements and a more balanced valuation assessment. While the company’s financial trends and quality metrics remain weak, recent quarterly results and some stabilisation in technical indicators suggest the possibility of a turnaround.

Investors should weigh the stock’s micro-cap risks, ongoing losses, and high leverage against the potential for recovery and improved market sentiment. The fair valuation grade indicates that the stock is no longer deeply undervalued but trades at a level that may reflect its current challenges. Given the mixed signals, a Sell rating advises prudence, with investors encouraged to monitor further developments closely.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today